isoflurane

Trade name: forane

Small moleculeapproved

Approved

Dec 18, 1979

Isoflurane (1-chloro-2, 2,2-trifluoroethyl difluoromethyl ether) a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Similar to many general anesthetics, the exact mechanism of the action has not been clearly delineated. Isoflurane reduces pain sensitivity (analgesia) and relaxes muscles. Isoflurane likely potentiates GABA-A and glycine receptor activity, which decreases motor function, inhibits receptor activity in the NMDA glutamate receptor subtypes and binds to glutamate receptors. Isoflurane is always administered in conjunction with air and/or pure oxygen. Often nitrous oxide is also used. Although its physical properties imply that anesthesia can be induced more rapidly than with halothane, its pungency can irritate the respiratory system, negating this theoretical advantage conferred by its physical properties. It is usually used to maintain a state of general anesthesia that has been induced with another drug, such as thiopentone or propofol. — NCATS

Clinical trial activity

90 trials · 92 clinical orgs · 7 marketing orgs

Phase 1
7
Phase 2
18
Phase 3
17
Phase 4
24

Earliest trial started Apr 1, 1994 (NCT00000251)

Timeline

1970s

  1. Dec 18, 1979

    Baxalta — Earliest FDA Approval

  2. Dec 18, 1979

    Baxalta — NDA Organization

  3. Dec 18, 1979

    Baxter — NDA Secondary Org

1990s

  1. Jan 25, 1993

    Hospira — Marketing Organization

  2. Jan 1, 1994

    Earliest Phase 2 Sponsor(trial)

  3. May 12, 1995

    Watson Pharmaceuticals — Marketing Organization

  4. Jun 27, 1995

    Piramal — Marketing Organization

  5. Oct 20, 1999

    Halocarbon Products — Marketing Organization

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Nov 4, 2025

    Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewDec 18, 1979

Chemistry & pharmacology

Loading structure…

SMILES

FC(F)OC(Cl)C(F)(F)F
Mol. weight
184.492 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
  • 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
  • 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
  • aerrane
  • aerrane
  • compound 469
  • compound 469
  • forane
  • forane
  • forane
  • forane
  • forene
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurane
  • isoflurano
  • isoflurano
  • isofluranum
  • isofluranum
  • isoforine
  • isorrane

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07099014Phase 3Sep 15, 2025Assistance Publique - Hôpitaux de Paris
NCT07152912N/ASep 4, 2025Ain Shams University
NCT07000526Phase 4Jul 31, 2025Universidad Autonoma de Madrid, Universidad Carlos III Madrid
NCT06252207N/AJan 15, 2025The Cleveland Clinic
NCT06624592Phase 3Nov 1, 2024Mayo Clinic
NCT06625606N/ASep 1, 2024Benha University
NCT06311604N/AJun 20, 2024University of Grenoble
NCT06387836N/AApr 23, 2024Fudan University
NCT05867472Phase 3Oct 10, 2023Canadian Institutes of Health Research (CIHR), University of Toronto
NCT06014138Phase 2/Phase 3 (Phase 3)Sep 30, 2023Sedana Medical, University of London
NCT05993039Early Phase 1 (Phase 1)Sep 1, 2023Louisiana State University, Our Lady of the Lake Regional Medical Center
NCT06418893Phase 2/Phase 3 (Phase 3)Aug 1, 2023Institute of Liver and Biliary Sciences, India
NCT05639686N/ADec 1, 2022Louisiana State University, Our Lady of the Lake Regional Medical Center
NCT05327296Phase 3Jun 30, 2022Columbia University, Sedana Medical
NCT05312385Phase 3Apr 28, 2022Sedana Medical, Vanderbilt University
NCT06809218Phase 3Apr 22, 2022Sedana Medical, University of California, San Francisco
NCT05314569Phase 1Apr 15, 2022Cairo University
NCT05693428N/AJan 22, 2022Astana Medical University
NCT05742789Phase 1Nov 30, 2021Astana Medical University
NCT05695287Phase 1Jan 22, 2021Astana Medical University
Showing 20 of 90 trials
Page 1 / 5

Organizations

Research & Development (92)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sedana MedicalAcademic/Hospital5412020
University of TorontoAcademic/Hospital5522009
Astana Medical UniversityAcademic/Hospital4432020
Duke UniversityAcademic/Hospital4432006
Fundação de Amparo à Pesquisa do Estado de São PauloAcademic/Hospital3022008
Vanderbilt UniversityAcademic/Hospital3222016
Ain Shams UniversityAcademic/Hospital2212021
Cairo UniversityAcademic/Hospital2222020
Columbia UniversityAcademic/Hospital2122003
Louisiana State UniversityAcademic/Hospital2022022
Mansoura UniversityAcademic/Hospital2212016
Nanjing Medical UniversityAcademic/Hospital2222007
National Institute on Drug Abuse (NIDA)Government2011994
Ohio State UniversityAcademic/Hospital2212015
Our Lady of the Lake Regional Medical CenterAcademic/Hospital2222022
Ruhr University BochumAcademic/Hospital2212014
RWTH Aachen UniversityAcademic/Hospital2122012
Sao Paulo State UniversityAcademic/Hospital2212008
University of BernAcademic/Hospital2212004
University of ChicagoAcademic/Hospital2211994
92 organizations
Page 1 / 5

Marketing (9)

OrganizationOrg typeRelationshipDate
BaxaltaFor profitNDADec 18, 1979
BaxterFor profitNDA2Dec 18, 1979
Halocarbon ProductsFor profitMKTGOct 20, 1999
HospiraFor profitMKTGJan 25, 1993
PiramalFor profitMKTGJun 27, 1995
PiramalFor profitSYNSep 30, 1994
PiramalFor profitMKTGJun 27, 1995
Shandong Lanjin Pharmaceuticals Co.,LtdFor profitMKTGNov 4, 2025
Watson PharmaceuticalsFor profitMKTGMay 12, 1995